Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis

Helen L Petsky,1 Chris J Cates,2 Kayleigh M Kew,3 Anne B Chang4,5

ABSTRACT
Background Asthma guidelines guide health practitioners to adjust treatments to the minimum level required for asthma control. As many people with asthma have an eosinophilic endotype, tailoring asthma medications based on airway eosinophilic levels (sputum eosinophils or exhaled nitric oxide, FeNO) may improve asthma outcomes. Objectives To synthesise the evidence from our updated Cochrane systematic reviews, for tailoring asthma medication based on eosinophilic inflammatory markers (sputum analysis and FeNO) for improving asthma-related outcomes in children and adults. Data sources Cochrane reviews with standardised searches up to February 2017. Study selection The Cochrane reviews included randomised controlled comparisons of tailoring asthma medications based on sputum analysis or FeNO compared with controls (primarily clinical symptoms and/or spirometry/peak flow). Results The 16 included studies of FeNO-based management (seven in adults) and 6 of sputum-based management (five in adults) were clinically heterogeneous. On follow-up, participants randomised to the sputum eosinophils strategy (compared with controls) were significantly less likely to have exacerbations (62 vs 82/100 participants with ≥1 exacerbation; OR 0.36, 95% CI 0.21 to 0.62). For the FeNO strategy, the respective numbers were adults OR 0.60 (95% CI 0.43 to 0.84) and children 0.58 (95% CI 0.45 to 0.75). However, there were no significant group differences for either strategy on daily inhaled corticosteroid dose (at end of study), asthma control or lung function. Conclusion Adjusting treatment based on airway eosinophilic markers reduced the likelihood of asthma exacerbations but had no significant impact on asthma control or lung function.

INTRODUCTION
The main aim of asthma guidelines is to provide an evidence-based approach to assist health professionals improve their patients’ asthma management, which involve using the minimal amount of medications to optimise asthma outcomes (minimal symptoms and exacerbations and high quality of life).1-3 Exacerbations are important as they cause anxiety to patients and are associated with increased healthcare cost.4 Monitoring asthma control is important in asthma management, although there is no single outcome measure that can adequately assess asthma control.5 Subjective measures usually involve a series of questions used for clinical assessment, and can include diary cards and quality of life (QoL) questionnaires. Traditional objective methods used to monitor asthma (but not control) include indices of spirometry/peak flow and airway hyper-responsiveness (AHR).6 Newer methods include measurement of airway inflammation, such as airway cellularity in induced sputum or fractional exhaled nitric oxide (FeNO), as phenotypes/endotypes of asthma are increasingly appreciated.7

The inflammation in airways of people with asthma can be predominantly eosinophilic or non-eosinophilic (including neutrophilic).8 Irrespective of the type of airway inflammation, inhaled corticosteroids (ICS) remain the major preventive therapy to control asthma symptoms, other than for children with mild intermittent asthma.3 However, ICS are more effective in reducing symptoms in patients with eosinophilic inflammation than those with neutrophilic inflammation.9 Thus, treatment tailoring based on objective eosinophilic inflammation may be helpful in improving asthma outcomes. Currently, clinically available technique are assessing airway cellularity and FeNO.10

Key messages
What is the key question?
► What is the overall outcome of trials that use eosinophilic markers (sputum eosinophil counts or exhaled nitric oxide levels) to tailor asthma treatment in children and adults?

What is the bottom line?
► Treatment tailored using eosinophilic markers results in fewer asthma attacks when compared with traditional management but did not impact on day-to-day reported symptoms, lung function or final daily inhaled corticosteroid doses.

Why read on?
► This systematic review combines 3 Cochrane reviews with 22 included studies, examining the updated evidence for objectively measuring inflammatory markers to personalise asthma management.
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart. FeNO, fractional exhaled nitric oxide; RCT, randomised controlled trial.

The increased attention to personalised medicine, which for asthma includes basing treatment on objective airway inflammation, is reflected by interest in our previous systematic review. We present an update to our previous review by providing an overview of three recent related Cochrane reviews, each of which addressed a different question as per the Participants Intervention Comparator Outcomes (PICO) framework. The objective of our systematic review is to evaluate the efficacy of tailoring asthma medications based on FeNO or sputum eosinophils (ie, eosinophilic-based strategy) in comparison with controls (clinical symptoms with or without spirometry/peak flow) for asthma-related outcomes in children and adults.

METHODS
Inclusion criteria, outcomes and analyses were a priori specified and documented in Cochrane review protocols and in the first versions of the three reviews on The Cochrane Library.

Eligibility, information sources, search strategy and study selection
We used Cochrane methods and searched (up to February 2017) for eligible randomised controlled trials (RCTs) that compared adjustment of asthma medications based on sputum eosinophils or FeNO levels with adjustment according to clinical symptoms (with or without spirometry/peak flow). As outlined in the reviews, searches used keywords in electronic sources (Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, EMBASE) and reference hand searching. Searches of bibliographies and texts were conducted to identify additional studies. Trials that included the use of other interventions were included if all participants had equal access to such interventions.

Participant inclusion criteria were children and adults with a diagnosis of asthma according to a guideline-defined criteria. Exclusion criteria were as follows: eosinophilic bronchitis, asthma related to an underlying lung disease such as bronchiectasis and chronic obstructive airway disease, or diagnostic categories such as ‘cough variant asthma’ and ‘wheezy bronchitis’ where controversies exist.

Data extraction
Titles and abstracts of all records returned by the literature search were reviewed independently in duplicate to identify potentially relevant trials. Searches of bibliographies and texts were conducted to identify additional studies. Using the prespecified criteria, two reviewers independently reviewed full texts to select trials for inclusion. There was no disagreement although it was planned that disagreement would have been resolved by third-party adjudication. We extracted information from each trial on (1) study characteristics, (2) intervention type and (3) outcomes, as described in our Cochrane reviews.

Risk of bias
Risk of bias for each included study was assessed using the Cochrane Risk of Bias tool available in the RevMan5 software. Seven components were assessed in duplicate as low, unclear or high risk of bias: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias.

Summary (outcome) measures
Primary outcomes were indices reflective of asthma exacerbations (defined by study authors) during the follow-up period. Secondary outcomes were mean differences (MDs) between
## Table 1: Characteristics of included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Description of intervention and control arms</th>
</tr>
</thead>
</table>
| Calhoun et al                | FeNO group n=115; Control group n=114 | Control group: National Heart, Lung and Blood Institute guidelines  
FeNO group: <22 ppb treatment stepped down  
22 to 35 maintain treatment  
>35 increase treatment |
| Cao et al                    | EOS strategy n=20; Control group n=21 | Control strategy: 'Standard clinical guidelines'  
EOS strategy: decrease ICS <1% eosinophils, keep ICS the same 1%–3% eosinophils, increase ICS if eosinophils ≥3% |
| Chlumsky et al               | EOS strategy n=30; Standard strategy n=25 | Standard strategy arm: GINA guidelines  
EOS strategy: decrease ICS if ≤3%, keep same if 4%–8%, increase ICS if ≥8% |
| de Jongste et al             | FeNO group n=75; Symptom group n=72 | All participants scored asthma symptoms in an electronic diary over 3 weeks. Aim to keep FeNO <20 ppb  
Symptom group based on symptom score: below range (<3) = step down, range 3 to 6 = step down/discontinue, range 10 to 60 = no change and range >60 = step up |
| Fleming et al                | Inflammatory group n=27; Symptom group n=28 | Symptom group: based on number of major exacerbations in the preceding 3 months and SABA use in preceding 2 weeks  
Inflammatory group: treatment aimed to keep sputum eosinophil counts <2.5% |
| Fritsch et al                | FeNO group n=22; Control group n=25 | FeNO group: therapy was based on symptoms, beta-agonist use, lung function and FeNO  
Control group: therapy based on symptoms, beta-agonists and lung function only |
| Green et al                  | Sputum management group n=37; BTS group n=37 | Sputum management group: anti-inflammatory treatment was based on maintenance of sputum eosinophil count below 3% with a minimum dose of anti-inflammatory treatment  
BTS management group: BTS/GINA guidelines |
| Hashimoto et al              | Internet strategy n=51; Conventional strategy n=38 | Internet strategy: had steroid dose adjusted based on the three components: electronic diary, in-built algorithm (which includes FeNO levels) and monitoring support  
Conventional strategy: GINA guidelines for the treatment of severe asthma |
| Honkoop et al                | FeNO group n=189; Controlled asthma group n=203 | Cluster randomisation (at general practice level)  
FeNO strategy: treatment targeted to keep FeNO <50 ppb  
Symptom strategy: ACT used including lung function |
| Jayaram et al                | Sputum strategy group n=50; Clinical strategy group n=52 | Sputum strategy: guided solely by induced sputum eosinophils to keep <2%  
Clinical strategy: Canadian Asthma Consensus Group Guidelines |
| Malerba et al                | Sputum strategy n=14; Clinical strategy n=14 | Sputum strategy: treatment based on sputum eosinophil (%) and FeNO (ppb)  
Decrease ICS <2% and ≤10 ppb  
Keep same 2%–3% and 11–20 ppb  
Increase ICS >3% and ≥20 ppb  
Symptom strategy: symptom scores, use of SABA and night-time symptoms |
| Peisman et al                | FeNO group n=49; Control group n=50 | FeNO group: treatment aimed to keep FeNO below 20 ppb  
Control group: GINA guidelines |
| Petsky et al                 | FeNO group n=31; Symptom group n=32 | FeNO group: treatment adjusted based on FeNO level and atopy status Elevated FeNO defined as:  
≥10 ppb with no positive SPT  
≥12 ppb with one positive SPT  
≥20 ppb with ≥2 positive SPT  
Control group: symptom diary cards |
| Pijnenburg et al             | FeNO group n=39; Symptom group n=46 | FeNO group: FeNO guided ICS dosing according to predetermined algorithm  
Symptom group: symptom scores influenced ICS dosing |
| Pike et al                   | FeNO group n=44; Standard management group n=46 | FeNO group: FeNO measurements and symptom control  
Standard management group: symptom control as per blinded clinician (relever use, FEV₁) |
| Powell et al                 | FeNO group n=111; Control group n=109 | FeNO group: sequential process, first FeNO concentrations used to adjust ICS dose, and second ACT score used to adjust the LABA dose  
Clinical group: Juniper ACT cut-off points defined as well-controlled asthma (ACT <0.75), partially controlled asthma (0.75 to 1.50) and uncontrolled asthma (>1.5) |
| Shaw et al                   | FeNO group n=58; Control group n=60 | FeNO group: FeNO >26 ppb, ICS was increased. If FeNO <16 ppb or <26 ppb on two separate occasions, treatment was decreased  
Control group: treatment was doubled if Juniper Asthma Control Score (JACS) >1.57 and treatment halved if JACS <1.57 for two consecutive months |
| Smith et al                  | 97 patients randomised from 110 patients | FeNO group: adjusted to keep FeNO <15 ppb at 250 mL/s  
Control group: dose adjustment based on asthma symptoms, night-time waking, bronchodilator use, variation in PEFR and FEV₁ |
| Syk et al                    | FeNO group n=87; Control group n=78 | FeNO group: keep FeNO level <24 ppb for women and <26 ppb for men  
Control group: treatment adjusted based on patient-reported symptoms, SABA use, physical examination and spirometry results |
| Szefler et al                | FeNO group n=276; Control group n=270 | FeNO group: standard treatment modified on the basis of measurements of FeNO  
Control group: National Asthma Education and Prevention Programme guidelines |

Continued
groups in objective measurements of asthma (FEV₁, peak flow, airway hyper-responsiveness), FeNO level, symptoms of asthma (as reported in Asthma Control Test (ACT)) or asthma-related QoL score and ICS dose at final visit.

Methods of analyses
The results from studies that met the inclusion criteria and reported any of the outcomes of interest were included in the subsequent meta-analyses. We a priori separated children from adult studies. All data were double entered (HLP/ABC or HLP/KK) and triple checked (CJC). We combined data for meta-analyses only where it was meaningful (ie, based on clinical and statistical criteria). We analysed dichotomous data as ORs and continuous data as MD, or as standardised MD if different measurement scales were used across studies. For dichotomous data, we reported the proportion of participants contributing to each outcome in comparison with the total number randomised. Generic inverse variance was used for rate ratio (RR) analysis of common events, where one subject may have more than one event. The RRs were taken from the published papers and SEs of the log RR were calculated from CIs or p values published in the papers. Numbers needed to treat (NNT) were calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator. Fixed effects were used throughout unless stated otherwise.

Any heterogeneity between the study results was described and tested to see if it reached statistical significance using a χ² test. We included the 95% CI estimated using a random-effects model whenever there were concerns about statistical heterogeneity. Heterogeneity was considered significant when the χ² value was >0.100. We used the I² statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity (>50%), we reported it and explored possible causes. Subgroup analysis was planned for (1) basis for adjustment of ICS in the control group (guideline-driven monitoring vs non-guideline driven); (2) use of spirometry or peak flow as an adjunctive monitoring tool for adjustment of medications (vs non-use of spirometry or peak flow); (3) baseline ICS dose at commencement of intervention (<800 µg/day vs >800 µg/day budesonide equivalent); (4) cut-offs for adjustment of medications.

We used the five Grading of Recommendations Assessment, Development and Evaluation (GRADE) considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it

Figure 2  Number of subjects who had ≥1 exacerbation over the study period (FeNO).
relates to the studies that contributed data to the meta-analyses for the prespecified outcomes.

RESULTS

Study selection and study characteristics
The searches in 2017 identified 1208 publications for FeNO-based strategy and 1213 for sputum. After screening, 30 and 7 papers respectively were retrieved but only 16 and 6, respectively, fulfilled the inclusion criteria (figure 1), including the nine studies from the previous review. The 22 studies included 16 FeNO-based trials (seven adults, nine children) and six sputum-based trials (five adults, one children), which included a total of 3500 participants, of whom 3208 completed the studies (91.7%).

Of the 22 studies included, 9 were single-centre studies, 2 were dual-centred and 11 were multicentred. Ten studies were in children or adolescents, and 12 involved adult participants. We classified studies into children/adolescent studies based on the mean age reported as opposed to the entry criteria. Nine studies were double-blind, parallel group trials, seven were single-blind, parallel group trials, and six studies had no blinding.

Paediatric studies

Table 2 Number of participants who had ≥1 exacerbation over the study period (FeNO)

<table>
<thead>
<tr>
<th>Study Group</th>
<th>N with exacerbation</th>
<th>N of group</th>
<th>Study Group</th>
<th>N with exacerbation</th>
<th>N of group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult</td>
<td></td>
<td></td>
<td>Adult</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honkoop et al27</td>
<td>23</td>
<td>189</td>
<td>30</td>
<td>203</td>
<td></td>
</tr>
<tr>
<td>Powell et al27</td>
<td>28</td>
<td>111</td>
<td>45</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>Berry et al</td>
<td>12</td>
<td>58</td>
<td>19</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Smith et al</td>
<td>14</td>
<td>46</td>
<td>11</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Syk et al28</td>
<td>15</td>
<td>93</td>
<td>25</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Paediatric studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>de Jongste et al26</td>
<td>9</td>
<td>75</td>
<td>12</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>Peisman et al24</td>
<td>11</td>
<td>49</td>
<td>22</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Ptefky et al20</td>
<td>6</td>
<td>31</td>
<td>15</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Pijnenburg et al28</td>
<td>7</td>
<td>42</td>
<td>10</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Pike et al22</td>
<td>37</td>
<td>44</td>
<td>38</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Szefler et al29</td>
<td>91</td>
<td>276</td>
<td>115</td>
<td>270</td>
<td></td>
</tr>
<tr>
<td>Verini et al20</td>
<td>16</td>
<td>32</td>
<td>26</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Voorend-van Bergen et al23</td>
<td>9</td>
<td>92</td>
<td>14</td>
<td>89</td>
<td></td>
</tr>
</tbody>
</table>

Results relates to the studies that contributed data to the meta-analyses for the prespecified outcomes.

Outcomes and synthesis of results

Primary (exacerbations)
In both adults and children, the number of participants with exacerbations (during the follow-up period 18–52 weeks) in the group whose treatment was adjusted according to FeNO were significantly lower than the control group; in adults, OR was 0.76 (95% CI 0.59 to 0.95; participants=1005; studies=5) and in children the OR was 0.36 (95% CI 0.26 to 0.48; participants=2284; studies=8). Based on the number of participants who had at least one exacerbation over the study period (table 2), the number needed to treat to benefit (NNTB) over 52 weeks was 12 (95% CI 8 to 16) in adults and 9 (95% CI 6 to 15) in children.

The exacerbation rate in the FeNO-strategy group was significantly lower than controls in the adult studies (RR 0.59, 95% CI 0.45 to 0.76; participants=1831; studies=3) and in the children studies (OR 0.36, 95% CI 0.26 to 0.48; participants=2284; studies=8). There was no significant difference between groups in the paediatric data and as statistical heterogeneity among studies was present, we used random-effects analysis to calculate the rate of exacerbations over 52 weeks (MD −0.37, 95% CI −0.80 to 0.06; participants=736; studies=4).

Figure 3 Number of subjects who had ≥1 exacerbation over the study period (SpEos).
Secondary outcomes

Inhaled corticosteroid (ICS) dose

For the FeNO-based studies, the meta-analysis found no significant group differences in the final ICS dose for adults or children (figure 4). In adults, the direction favoured the FeNO strategy (MD between groups was −147.15 µg budesonide equivalent; 95% CI −380.85 to 86.56; p=0.22; participants=582; studies=4), but in children in favour of the control strategy (MD 65.88 µg budesonide equivalent, 95% CI −86.71 to 218.47; p=0.40; participants=317; studies=3) (figure 4).

All five studies that used sputum eosinophils to adjust treatment reported no differences in doses of ICS used between groups (online supplementary figure 1). The SDs for the groups were not available in Jayaram et al’s paper24 and were estimated based on the data from Green et al’s paper.23 The mean dose of ICS per person per day (µg budesonide equivalent) between groups was non-significant in adult studies (MD 0.67, 95% CI −154.39 to 155.73; p=0.99; participants=262; studies=4). Likewise, there was no difference in daily ICS doses in the sole paediatric study (MD 67.0, 95% CI −264.81 to 398.81; p=0.69; participants=54).

Symptom scores and other outcomes

Symptom or ACT scores did not significantly differ between groups for FeNO studies in either adults or children (online supplementary figure 2). In adults (four studies), the direction of the difference in scores favoured the FeNO strategy, MD was −0.08 (95% CI −0.18 to 0.01; p=0.09; participants=707), but the direction in children favoured the control group: mean difference was 0.14 (95% CI −0.18 to 0.47; p=0.39; participants=724; studies=2). For the sputum-based studies, the two studies that reported on symptom scores also described no significant difference in symptom scores between groups.23 24 Likewise, for the outcome of asthma QoL scores, there were no significant group differences for the FeNO-based studies in adults and children (online supplementary Figure 3).

In adults, there were only two studies and the MD in children was 0.09 (95% CI −0.08 to 0.26; p=0.29; studies=3).

There were insufficient data reported from the individual studies to undertake a meta-analyses for the other secondary outcomes (FEV₁, AHR, rescue beta-agonist use). While FEV₁ was reported in all studies, data points were not provided; the studies described they found no difference between the participants who had treatment adjusted to inflammatory markers in comparison with the control group.

Subgroup analyses

As per table 1, 8 of the 16 FeNO-based studies23 24 25 26 27 28 29 30 used guideline-driven monitoring for the control group. In this subgroup analysis based on trials that used guideline-driven monitoring, the significant difference was no longer present for the primary outcome of number of participants who had one or more exacerbations (OR 0.87, 95% CI 0.51 to 0.90). The subgroup analyses results for ‘cut-off FeNO values’ were similar to the main analyses; the FeNO group had significantly fewer exacerbations. As there were insufficient data, we could not undertake subgroup analyses for the other planned subgroups.

Risk of bias in individual studies

The risk of bias diagram (figure 5) shows that eight studies18 20 21 22 23 24 25 26 were judged as having good methodological quality, but in all studies there was either insufficient details about allocation concealment and/or adequacy of blinding. Seven studies22 23 24 25 26 27 28 were open label or single blinded (six in FeNO studies, one in sputum-driven studies). When data from the six open-label FeNO-driven studies21 22 23 24 25 26 were removed, the primary outcome results (exacerbations) did not change. In adults, the number of participants who had one or more exacerbations over the study period OR 0.63 (95% CI 0.41 to 0.96; participants=432; studies=3) and exacerbation rates (RR 0.61, 95% CI 0.45, 0.82; participants=661, studies=4) in children, the number of participants who had one or more exacerbations over the study period OR 0.67 (95% CI 0.50 to 0.89; participants=887, studies=3) were both significantly reduced compared with the control group. As there were insufficient data, we could not undertake subgroup analyses for the other planned subgroups.
In this meta-analysis, we combined data from our three Cochrane reviews that evaluated the efficacy of tailoring asthma medications (ICS predominantly) based on airway eosinophilic markers (FeNO or sputum eosinophils) in comparison with controls (clinical symptoms with or without spirometry/peak flow) for asthma-related outcomes in children and adults. Based on 22 studies involving 3500 adults and children (3208 completed), we found that children and adults randomised to either eosinophilic marker strategy (compared with controls) were significantly less likely to experience an exacerbation during the follow-up period (4.5–24 months). The exacerbation rate was also significantly lower in adults randomised to the FeNO or sputum strategy (compared with controls) but not in children. There was not a significant difference in the final dose of ICS in either children or adults. For both FeNO and sputum-based strategies, there was no difference between groups for all secondary outcomes (FEV1, ACT, QoL, airway hyper-responsiveness or beta2 agonist use).

In this review updated from our previous combined meta-analyses, the data on sputum remained unchanged, that is, using sputum to guide asthma therapies in adults is beneficial for the outcome of reducing exacerbations. The new single paediatric study found no significant difference between the groups for this outcome, although it favoured the sputum-based strategy. However, the OR for the combined adult and paediatric studies remained unchanged at 0.36, but the 95% CI was marginally smaller from 0.20 to 0.64 to 0.21 to 0.62.

In contrast to the data for sputum, the additional 10 studies included in the FeNO strategy analyses altered the previous ‘no benefit’ found in our previous review to ‘some benefit’ as using a FeNO-based strategy reduced the number of participants with asthma exacerbations during the follow-up period in both children and adults. However, the benefit was inconsistent as there was no longer any significant difference between groups in the sensitivity analyses for adults, while in children there were no group differences for exacerbation rate. While these new data are somewhat supportive of authors who previously advocated using FeNO levels to tailor medications, we do not believe there is currently sufficient evidence to universally use FeNO to monitor airway inflammation recommended by others.

In contrast to the favourable data in the outcome of exacerbations for both sputum and FeNO-based strategies, the data for other asthma outcomes (FEV1, symptom scores, QoL and beta2 agonist use) remained unchanged, that is, neither sputum and FeNO-based strategies were shown to confer any advantage over the control arms. There may be several reasons for this including the known discordance between asthma control and exacerbations. While exacerbations are an important outcome, arguably subjective measures of asthma control are also important. Thus, although our findings demonstrate using airway eosinophilic markers to guide medications in future exacerbations, it is debatable whether either strategy should be universally advocated. Sputum analysis is restricted to laboratories with specific expertise, is relatively time consuming and is not always successful, particularly in young children. Use of FeNO universally will add a substantial cost to the millions of people who have asthma. Also, currently there is no evidence-based algorithm on how to adjust treatment based on FeNO levels (or indeed to sputum eosinophil levels) and the various guidelines (such as GINA, BTS, NAC) differ on when and how to step up and down asthma therapies. Nevertheless, using airway eosinophilic markers to guide asthma therapy is most...
Table 3  Summary of findings for the main comparisons: FeNO-based adult studies

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Risk with asthma treatment tailored on clinical symptoms®</th>
<th>Risk with asthma treatment tailored on FeNO</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of participants who had ≥1 exacerbations over the study period Follow-up: range 18 weeks to 52 weeks</td>
<td>25 per 100 (13 to 22)</td>
<td>17 per 100 (13 to 22)</td>
<td>OR 0.60 (0.43 to 0.84)</td>
<td>1005 (5 RCTs)</td>
<td>Moderate1</td>
<td>–</td>
</tr>
<tr>
<td>No of exacerbations per 52 weeks (exacerbation rates) Follow-up: mean 52 weeks</td>
<td>The control group ranged from 0.23 to 0.9 exacerbations per 52 weeks</td>
<td>Rate ratio 0.59 (0.45 to 0.77)</td>
<td>–</td>
<td>842 (5 RCTs)</td>
<td>Moderate1</td>
<td>–</td>
</tr>
<tr>
<td>ICS dose at final visit Follow-up: range 18 weeks to 52 weeks</td>
<td>The mean ICS dose taken by the control group at final visit was 659 µg</td>
<td>The mean ICS dose taken in the FeNO groups was 17.01 lower (101.75 lower to 67.72 more) 577 µg</td>
<td>–</td>
<td>582 (4 RCTs)</td>
<td>Very low1</td>
<td>A random-effects sensitivity analysis gave a very imprecise result: MD −147.15 (95% CI −380.85 to 183.56)</td>
</tr>
</tbody>
</table>

GRADE Working Group grades of evidence:

High quality: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

†The control group risks were calculated as a mean of the scores or events in the control groups of the studies contributing to each analysis. We could not calculate a control risk because we did not have information for each arm of the studies, just ratios between them.

FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroids; MD, mean difference; RCT, randomised controlled trial.

Table 4  Summary of findings for the main comparisons: FeNO-based paediatric studies

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Risk with clinical symptoms</th>
<th>Risk with asthma treatment tailored on FeNO</th>
<th>Relative effect (95% CI)</th>
<th>Number of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of participants who had ≥1 exacerbations over the study period (48.5 weeks)</td>
<td>40 per 100 (23 to 33)</td>
<td>28 per 100 (23 to 33)</td>
<td>OR 0.58 (0.45 to 0.75)</td>
<td>1279 (8 RCTs)</td>
<td>Moderate1</td>
<td>–</td>
</tr>
<tr>
<td>No of asthma exacerbations per 52 weeks (exacerbation rate)</td>
<td>The mean number of asthma exacerbations per 52 weeks (exacerbation rate) was 1.66</td>
<td>The mean number of asthma exacerbations per 52 weeks (exacerbation rate) in the intervention group was 0.37 lower (0.8 lower to 0.06 higher)</td>
<td>MD −0.37 (−0.8 to 0.06)</td>
<td>736 (4 RCTs)</td>
<td>Very low1</td>
<td>–</td>
</tr>
<tr>
<td>ICS dose at final visit (budesonide equivalent)</td>
<td>The mean ICS dose at final visit (budesonide equivalent) was 483 µg/day</td>
<td>The mean ICS dose at final visit (budesonide equivalent) in the intervention group was 63.95 µg/day higher (51.89 lower to 179.79 higher)</td>
<td>–</td>
<td>317 (3 RCTs)</td>
<td>Moderate1</td>
<td>–</td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroids; MD, mean difference; RCT, randomised controlled trial.
likely to be beneficial to the subset of people with frequent asthma exacerbations.

The data on the FeNO-based studies also need to be considered in light of several issues. First, only one of the 16 included studies using FeNO considered presence or severity of atopy in their algorithm of management although some but not all subjects were atopic. FeNO is higher when eosinophilic inflammation is present; however, it is also higher in other conditions (eg, atopy, allergic rhinitis, eczema). Second, the cut-offs of FeNO used for stepping up or down therapy differed between studies (range 0.18–50 ppb). Pijnenburg et al stepped up or down therapy differed between studies (range 0.18–50 ppb). Pijnenburg et al et al. (paediatric study) subjects had the highest mean daily dose of ICS, and subjects in this study also had quite high FeNO at the final visit (approximately 25.5 ppb in FeNO group, 36.7 in controls). Disconcertingly, use of the highest mean daily dose of ICS, and subjects in this study also had quite high FeNO at the final visit (approximately 25.5 ppb in FeNO group, 36.7 in controls). Disconcertingly, use of the FeNO strategy did not result in a lower FeNO level at the end of trial. Moreover, some of the algorithms used a safety net to avoid excessively high doses of ICS in some participants whose FeNO remained high. Third, as reported in risk of bias table (table 2), obtaining accurate FeNO measurements at each visit could not be obtained, either due to a faulty analyser or technical issues. Also, many aspects need to be considered when analysing FeNO; this includes the timing of spirometry (transiently reduces FeNO), food and beverage, circadian rhythm, smoking history, ambient NO and exercise. Lastly, FeNO values may not always reflect levels of airway eosinophilia as shown in a RCT using mepoluzimab.

Limitations of review

This systematic review is limited to 22 studies with 3208 subjects completing the trials. While the studies share some common issues, there are also substantial differences, notably, the definition of asthma exacerbation, the participants, how the decision to prescribe oral steroids was made, the cut-off levels for FeNO and sputum eosinophils were different, the control strategies (that often used uses multiple measures) and how medications were adjusted. Also, 7 of the 16 FeNO-based studies were supported by the FeNO manufacturers, and although we are unaware of any publication bias, we cannot be certain of its existence.

CONCLUSION

Tailoring of asthma therapy based on FeNO or sputum eosinophils has been shown to be effective in decreasing asthma exacerbations in adults. Adjusting treatment based on FeNO levels for children tended to decrease asthma exacerbations at the expense of increased ICS doses. At present, despite their popularity, there is insufficient evidence to advocate their use in routine clinical practice.

Further, data starting with meta-analyses based on individual patient data (IPD) of all the studies may further inform the efficacy of strategies based on airway eosinophilic markers. If IPD meta-analysis does not shed more light, e.g., the change in FeNO before medications are adjusted, further RCTs in both adults and children are then required. Ideally, these RCTs should include stratification for example, high versus low doses of ICS, and eosinophilic versus non-eosinophilic asthma and cost-effectiveness.

Contributors All authors contributed and reviewed the manuscript. HLP, ABC and KMK extracted the data and performed the analysis. CJC triple checked all data and provided statistical support.

Funding Asthma Australia—HLP is supported by Early Career Fellowship; National Health and Medical Research Council—10058213 Practitioner Fellowship for ABC; Programme Grants for Applied Research—13/89/14 Cochrane Programme Grant (KMK and CJC).

Competing interests HLP, and ABC have conducted a randomised controlled trial in children on this subject. Other authors have no competing interests to declare.

Patient consent Not required.
Provenance and peer review  Not commissioned; externally peer reviewed.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
10 Wark PA, Gibson PG. Clinical usefulness of inflammatory markers in asthma. Am J Respir Crit Med 2003;2;11–19.